Pay-for-delay patent settlements on the rise, prompting fierce debate
Patent dispute settlements between brand-name and generic drug manufacturers that delay the time lower-cost medications reach the market are sharply rising, according to a recent Federal Trade Commission staff report. FTC...To view the full article, register now.
Already a subscriber? Click here to view full article